hydrochlorothiazide has been researched along with Cancer of Skin in 70 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent studies reported the association between increased risk of nonmelanoma skin cancers (NMSCs) and the use of hydrochlorothiazide (HCTZ), one of the most commonly prescribed diuretic, antihypertensive drug, over the world." | 8.02 | Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. ( Bigagli, E; Cinci, L; Colucci, R; D'Ambrosio, M; Lodovici, M; Luceri, C; Mugelli, A; Nardini, P; Portelli, F, 2021) |
| "In 2018, the Pharmacological Risk Assessment Committee alerted to a potential relationship between accumulated hydrochlorothiazide dosage and the risk of non-melanoma skin cancer." | 8.02 | Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. ( Lecaros-Astorga, DA; Martin-Arias, LH; Molina-Guarneros, JA; Rodríguez-Jiménez, P; Sainz-Gil, M, 2021) |
| "There are concerns that hydrochlorothiazide may increase the risk of incident nonmelanoma (cutaneous squamous cell carcinoma [cSCC], basal cell carcinoma [BCC]) and melanoma skin cancer, with regulatory agencies and societies calling for additional studies." | 8.02 | Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. ( Azoulay, L; Nirantharakumar, K; Pottegård, A; Rouette, J; Yin, H, 2021) |
| " To assess the effects of photosensitizing drugs voriconazole and hydrochlorothiazide (HCTZ) on the enhancement of UV-induced inflammatory responses and UV-induced tumorigenesis, we utilized Xpa-knockout mice, which is DNA repair-deficient and more susceptible to UV-induced inflammation and tumor development than wild-type mice." | 7.88 | Inflammation Due to Voriconazole-induced Photosensitivity Enhanced Skin Phototumorigenesis in Xpa-knockout Mice. ( Hosaka, C; Kunisada, M; Nishigori, C; Takemori, C; Yamano, N, 2018) |
| "Hydrochlorothiazide is associated with an increased risk for NMSC (especially SCC) and melanoma in non-Asian countries, whereas bendroflumethiazide and indapamide are not associated with a meaningful risk for skin cancers." | 5.22 | Associations of thiazide use with skin cancers: a systematic review and meta-analysis. ( Chen, YH; Chi, CC; Hung, MJ; Lai, CC; Lai, EC; Shao, SC, 2022) |
| "Recent studies reported the association between increased risk of nonmelanoma skin cancers (NMSCs) and the use of hydrochlorothiazide (HCTZ), one of the most commonly prescribed diuretic, antihypertensive drug, over the world." | 4.02 | Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. ( Bigagli, E; Cinci, L; Colucci, R; D'Ambrosio, M; Lodovici, M; Luceri, C; Mugelli, A; Nardini, P; Portelli, F, 2021) |
| "In 2018, the Pharmacological Risk Assessment Committee alerted to a potential relationship between accumulated hydrochlorothiazide dosage and the risk of non-melanoma skin cancer." | 4.02 | Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. ( Lecaros-Astorga, DA; Martin-Arias, LH; Molina-Guarneros, JA; Rodríguez-Jiménez, P; Sainz-Gil, M, 2021) |
| "There are concerns that hydrochlorothiazide may increase the risk of incident nonmelanoma (cutaneous squamous cell carcinoma [cSCC], basal cell carcinoma [BCC]) and melanoma skin cancer, with regulatory agencies and societies calling for additional studies." | 4.02 | Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. ( Azoulay, L; Nirantharakumar, K; Pottegård, A; Rouette, J; Yin, H, 2021) |
| "The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes." | 3.91 | Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study. ( Hsu, CK; Lai, EC; Lee, CN; Liao, TC; Pedersen, SA; Pottegård, A; Schmidt, SAJ; Shao, SC, 2019) |
| " To assess the effects of photosensitizing drugs voriconazole and hydrochlorothiazide (HCTZ) on the enhancement of UV-induced inflammatory responses and UV-induced tumorigenesis, we utilized Xpa-knockout mice, which is DNA repair-deficient and more susceptible to UV-induced inflammation and tumor development than wild-type mice." | 3.88 | Inflammation Due to Voriconazole-induced Photosensitivity Enhanced Skin Phototumorigenesis in Xpa-knockout Mice. ( Hosaka, C; Kunisada, M; Nishigori, C; Takemori, C; Yamano, N, 2018) |
| "We found no increased skin cancer risk when analyzing cohort studies or studies that corrected for important covariates." | 3.01 | The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis. ( Daams, JG; de Rie, MA; Heisel, AGU; Olde Engberink, RHG; van den Born, BH; Vogt, L; Vuurboom, MD, 2023) |
| "Many medications are associated with phototoxicity or photoallergy, the two types of photosensitivity." | 3.01 | What is the relationship between photosensitizing drugs and skin cancer? ( Ferrington, L; Rhodes, A; Weidman-Evans, E, 2023) |
| "The mean age for cutaneous and lip squamous cell carcinoma development was 73." | 2.82 | Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis. ( Barboza, CAG; de Castro, RD; de Lisboa Lopes Costa, A; de Macedo Andrade, AC; Felix, FA; França, GM; Ribeiro, ILA, 2022) |
| "Patients within the lip cancer and oral cancer groups were accepted with a history of non-melanoma skin cancer (NMSC)." | 2.82 | Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population? ( Carney, K; Cousins, M, 2022) |
| "Non-melanoma skin cancer is the most prevalent malignancy in fair-skinned people and its incidence is increasing." | 2.66 | Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. ( Borges-Costa, J; Garrido, PM, 2020) |
| " These results do not modify the benefit/risk ratio but should lead to propose preventive mesures: identification of high risk population, avoidance of this drug if possible in immunocompromised patients or with previous skin cancer, regular skin examination in case of long term use of hydrochlorothiazide." | 2.61 | [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. ( Becquart, O; Bourrain, JL; Du-Thanh, A; Duflos, C; Guillot, B, 2019) |
| "Hydrochlorothiazide and skin cancer Hydrochlorothiazide is a frequently prescribed diuretic with known photosensitizing properties." | 2.61 | [Hydrochlorothiazide and skin cancer]. ( Olde Engberink, RHG; van den Born, BH; van der Hoeven, NV; Zwinderman, AH, 2019) |
| "Pseudo-Sezary syndrome is a benign lymphoproliferative disorder, which clinically and pathologically mimics true Sezary syndrome." | 2.52 | Drug-induced pseudo-Sezary syndrome: a case report and literature review. ( Reeder, MJ; Wood, GS, 2015) |
| "We evaluated melanoma and nonmelanoma skin cancer among hydrochlorothiazide users with 3 different cohorts as each allows assessment of different potential cofounders/effect modifiers, including race/ethnicity." | 1.91 | Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity. ( Abrahamowicz, M; Bernatsky, S; Birck, MG; Liu, JL; Machado, MAA; Moura, CS; Pilote, L, 2023) |
| "BCC recurrences were statistically significant with age, longer follow-up, and positive margins after excision in HCTZ users (p = 0." | 1.91 | The effect of hydrochlorothiazide on the recurrence of nonmelanoma skin cancer: a 7-year retrospective study comprising 300 patients. ( Akıncı, K; Albayati, A; Özkan, B; Savran, S; Uysal, AÇ; Uysal, Pİ, 2023) |
| "Over 80% of skin cancer is due to acquired mutations, and nitrosamines, which are contained as contamination in certain batches of the most commonly distributed drugs worldwide (such as sartans, ACE inhibitors, ranitidine, metformin, hydrochlorothiazide, rifampicin, and a number of others." | 1.91 | MULTIPLE BCCS AND DYSPLASTIC NEVI AFTER ACE INHIBITORS (ENALAPRIL/PERINDOPRIL): THE ROLE OF NITROSAMINE CONTAMINATION/AVAILABILITY AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR. ( Kordeva, S; Tchernev, G, 2023) |
| " The aim of this study was to investigate the association between hydrochlorothiazide use and incidence of skin cancer in a cohort of unselected Caucasian adults, taking dosing into account." | 1.91 | Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study. ( Bos, J; De Bock, GH; De Vos, S; Greven, N; Haisma, MS; Hak, E; Horváth, B; Logendran, M; Rácz, E; van der Vegt, B, 2023) |
| "Hydrochlorothiazide (HCT) has been suggested to induce photosensitivity, thereby increasing the incidence of skin cancers." | 1.91 | Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study. ( Böhm, M; Götzinger, F; Hardtstock, F; Krieger, J; Kunz, M; Lauder, L; Mahfoud, F; Maywald, U; Schulz, M; Wilke, T, 2023) |
| "Hydrochlorothiazide (HCTZ) is a frequently prescribed diuretic that exhibits photosensitizing properties." | 1.91 | Does systemic hydrochlorothiazide increase the risk of developing ultraviolet radiation-induced skin tumours in hairless mice? ( Al-Chaer, RN; Lerche, CM; Wulf, HC, 2023) |
| "We recommend regular skin cancer screening, moderate ordination of photosensitizing medication, but above all comprehensive clarification of possible risks." | 1.72 | The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. ( Druchkiv, V; Garbe, C; Hagenström, K; Mehlan, J; Schuettauf, F; Spitzer, MS; Ueberschaar, J, 2022) |
| "We calculated odds ratios (ORs) for skin cancer and NMSC associated with hydrochlorothiazide using conditional logistic regression." | 1.72 | Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide? ( Cione, E; De Sarro, G; Gallelli, L; Gerace, A; Guerra, A; Leuzzi, G; Longo, L; Luciani, F; Muraca, L; Natale, V; Scaramuzzino, A; Scuteri, A; Siniscalchi, A; Vasapollo, P; Vasta, G; Zampogna, S, 2022) |
| "The incidence of skin cancer is increasing because of the ageing population and ultraviolet exposure, and previous studies have revealed that long-term use of hydrochlorothiazide (HCTZ), an antihypertensive agent, has been associated with an increased risk of nonmelanoma skin cancer (NMSC)." | 1.62 | Use of hydrochlorothiazide and risk of nonmelanoma skin cancer in Koreans: a retrospective cohort study using administrative healthcare data. ( Choi, JW; Kim, JC; Kim, YC, 2021) |
| "In this European Mediterranean population, a high cumulative use of HCTZ was related to an increased risk of KC with a clear dose-response pattern." | 1.62 | Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain. ( Díaz, Y; Duarte-Salles, T; Huerta, C; León-Muñoz, LM; Llorente, A; Montero-Corominas, D; Pottegård, A; Puente, D, 2021) |
| "The publication of increased risk of skin cancer with hydrochlorothiazide use has led to a marked decline in the use of hydrochlorothiazide in Denmark." | 1.62 | Use of hydrochlorothiazide in Denmark following publication of skin cancer risk findings. ( Bech, BH; Christensen, B; Pedersen, SA; Pottegård, A, 2021) |
| "High cumulative use of HCTZ may have a chemopreventive effect against the development of melanoma and NMSC with clear cumulative dose-response and duration-response relationships in South Korea." | 1.56 | Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea. ( Jue, MS; Lee, Y; Park, E, 2020) |
| "Hydrochlorothiazide exposure was associated with an increased risk of SCC, BCC and lip cancer that is not explained following adjustment for smoking and BMI." | 1.56 | Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. ( Kurz, X; Morales, DR; Pacurariu, A; Slattery, J, 2020) |
| "Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma." | 1.51 | Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. ( Friis, S; Gaist, D; Hölmich, LR; Johannesdottir Schmidt, SA; Pedersen, SA; Pottegård, A, 2019) |
| " We found clear dose-response relationships between hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1." | 1.48 | Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. ( Friis, S; Gaist, D; Hölmich, LR; Pedersen, SA; Pottegård, A; Schmidt, SAJ, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.43) | 29.6817 |
| 2010's | 18 (25.71) | 24.3611 |
| 2020's | 51 (72.86) | 2.80 |
| Authors | Studies |
|---|---|
| Tiba, APL | 1 |
| Cury-Martins, J | 1 |
| Miyashiro, DR | 1 |
| Sanches, JA | 1 |
| de Haan-Du, J | 1 |
| Landman, GWD | 1 |
| Groenier, KH | 1 |
| Vissers, PAJ | 1 |
| Louwman, MWJ | 1 |
| Kleefstra, N | 1 |
| de Bock, GH | 2 |
| Gallelli, L | 1 |
| Cione, E | 1 |
| Siniscalchi, A | 1 |
| Vasta, G | 1 |
| Guerra, A | 1 |
| Scaramuzzino, A | 1 |
| Longo, L | 1 |
| Muraca, L | 1 |
| De Sarro, G | 1 |
| Leuzzi, G | 1 |
| Gerace, A | 1 |
| Scuteri, A | 1 |
| Vasapollo, P | 1 |
| Natale, V | 1 |
| Zampogna, S | 1 |
| Luciani, F | 1 |
| Mehlan, J | 1 |
| Ueberschaar, J | 1 |
| Hagenström, K | 1 |
| Garbe, C | 1 |
| Spitzer, MS | 1 |
| Druchkiv, V | 1 |
| Schuettauf, F | 1 |
| de Macedo Andrade, AC | 1 |
| Felix, FA | 1 |
| França, GM | 1 |
| Ribeiro, ILA | 1 |
| Barboza, CAG | 1 |
| de Castro, RD | 1 |
| de Lisboa Lopes Costa, A | 1 |
| Carney, K | 1 |
| Cousins, M | 1 |
| VanWormer, JJ | 1 |
| Abokede, EB | 1 |
| Berg, RL | 1 |
| Shao, SC | 2 |
| Lai, CC | 1 |
| Chen, YH | 1 |
| Lai, EC | 2 |
| Hung, MJ | 1 |
| Chi, CC | 1 |
| Bigagli, E | 2 |
| Mugelli, A | 2 |
| Mancia, G | 1 |
| Lerche, CM | 1 |
| Al-Chaer, RN | 1 |
| Wulf, HC | 1 |
| Bard, JT | 1 |
| Kornmehl, HA | 1 |
| Smith, RJ | 1 |
| Götzinger, F | 1 |
| Wilke, T | 1 |
| Hardtstock, F | 1 |
| Krieger, J | 1 |
| Maywald, U | 1 |
| Kunz, M | 1 |
| Lauder, L | 1 |
| Schulz, M | 1 |
| Mahfoud, F | 1 |
| Böhm, M | 1 |
| Haisma, MS | 1 |
| Greven, N | 1 |
| Logendran, M | 1 |
| Bos, J | 1 |
| van der Vegt, B | 1 |
| Horváth, B | 1 |
| De Vos, S | 1 |
| Hak, E | 1 |
| Rácz, E | 1 |
| Tchernev, G | 2 |
| Kordeva, S | 1 |
| Heisel, AGU | 1 |
| Vuurboom, MD | 1 |
| Daams, JG | 1 |
| de Rie, MA | 1 |
| Vogt, L | 2 |
| van den Born, BH | 3 |
| Olde Engberink, RHG | 2 |
| Azoulay, L | 2 |
| St-Jean, A | 1 |
| Dahl, M | 1 |
| Quail, J | 1 |
| Aibibula, W | 1 |
| Brophy, JM | 1 |
| Chan, AW | 1 |
| Bresee, L | 1 |
| Carney, G | 1 |
| Eltonsy, S | 1 |
| Tamim, H | 1 |
| Paterson, JM | 1 |
| Platt, RW | 1 |
| Weidman-Evans, E | 1 |
| Rhodes, A | 1 |
| Ferrington, L | 1 |
| Özkan, B | 1 |
| Savran, S | 1 |
| Akıncı, K | 1 |
| Albayati, A | 1 |
| Uysal, Pİ | 1 |
| Uysal, AÇ | 1 |
| Birck, MG | 1 |
| Moura, CS | 2 |
| Machado, MAA | 1 |
| Liu, JL | 1 |
| Abrahamowicz, M | 2 |
| Pilote, L | 2 |
| Bernatsky, S | 2 |
| Danieli, C | 1 |
| Bright, HR | 1 |
| Chandy, SJ | 1 |
| George, R | 1 |
| Jensen, GB | 1 |
| Humbert, X | 1 |
| Dolladille, C | 1 |
| Chrétien, B | 1 |
| Sassier, M | 1 |
| Fedrizzi, S | 1 |
| Puddu, PE | 1 |
| Alexandre, J | 1 |
| Pedersen, SA | 8 |
| Pottegård, A | 13 |
| Schmidt, SAJ | 3 |
| Lee, CN | 1 |
| Hsu, CK | 1 |
| Liao, TC | 1 |
| Park, E | 2 |
| Lee, Y | 2 |
| Jue, MS | 2 |
| Morales, DR | 1 |
| Pacurariu, A | 1 |
| Slattery, J | 1 |
| Kurz, X | 1 |
| Taherifard, E | 1 |
| Morales, D | 1 |
| Randhawa, A | 1 |
| Wylie, G | 1 |
| Garrido, PM | 1 |
| Borges-Costa, J | 1 |
| Daniels, B | 1 |
| Pearson, SA | 1 |
| Vajdic, CM | 1 |
| Buckley, NA | 1 |
| Zoega, H | 1 |
| Freeman, C | 1 |
| Hull, C | 1 |
| Sontheimer, R | 1 |
| Curtis, J | 1 |
| Adalsteinsson, JA | 1 |
| Muzumdar, S | 1 |
| Waldman, R | 1 |
| Hu, C | 1 |
| Wu, R | 1 |
| Ratner, D | 1 |
| Ungar, J | 1 |
| Silverberg, JI | 1 |
| Olafsdottir, GH | 1 |
| Kristjansson, AK | 1 |
| Tryggvadottir, L | 1 |
| Jonasson, JG | 1 |
| Rodríguez-Jiménez, P | 2 |
| Lecaros-Astorga, D | 1 |
| Martin-Arias, LH | 2 |
| Rouette, J | 1 |
| Yin, H | 1 |
| Nirantharakumar, K | 1 |
| Letellier, T | 1 |
| Leborgne, F | 1 |
| Kerleau, C | 1 |
| Gaultier, A | 1 |
| Dantal, J | 1 |
| Ville, S | 1 |
| Aschenbrenner, DS | 1 |
| Kim, JC | 1 |
| Kim, YC | 1 |
| Choi, JW | 1 |
| Lecaros-Astorga, DA | 1 |
| Molina-Guarneros, JA | 1 |
| Sainz-Gil, M | 1 |
| Pease, DR | 1 |
| Martinez-Escala, ME | 1 |
| Jimenez, J | 1 |
| Guitart, J | 1 |
| West, DP | 1 |
| Nardone, B | 1 |
| Eworuke, E | 1 |
| Haug, N | 1 |
| Bradley, M | 1 |
| Cosgrove, A | 1 |
| Zhang, T | 1 |
| Dee, EC | 1 |
| Adimadhyam, S | 1 |
| Petrone, A | 1 |
| Lee, H | 1 |
| Woodworth, T | 1 |
| Toh, S | 1 |
| León-Muñoz, LM | 1 |
| Duarte-Salles, T | 1 |
| Llorente, A | 1 |
| Díaz, Y | 1 |
| Puente, D | 1 |
| Montero-Corominas, D | 1 |
| Huerta, C | 1 |
| Hollestein, LM | 1 |
| Arnspang Pedersen, S | 1 |
| Cinci, L | 1 |
| D'Ambrosio, M | 1 |
| Nardini, P | 1 |
| Portelli, F | 1 |
| Colucci, R | 1 |
| Lodovici, M | 1 |
| Luceri, C | 1 |
| Bech, BH | 1 |
| Christensen, B | 1 |
| Gaist, D | 5 |
| Hölmich, LR | 3 |
| Friis, S | 3 |
| Schmutz, JL | 2 |
| Johannesdottir Schmidt, SA | 1 |
| Kunisada, M | 1 |
| Yamano, N | 1 |
| Hosaka, C | 1 |
| Takemori, C | 1 |
| Nishigori, C | 1 |
| Olde-Engberink, R | 1 |
| Heymann, WR | 1 |
| Geyer, S | 1 |
| Yazdi, AS | 1 |
| van Veelen, A | 1 |
| Nielen, JTH | 1 |
| van Geel, R | 1 |
| Croes, S | 1 |
| Faconti, L | 1 |
| Ferro, A | 1 |
| Webb, AJ | 1 |
| Cruickshank, JK | 1 |
| Chowienczyk, PJ | 1 |
| Han, S | 1 |
| Wolfe, CM | 2 |
| Angnardo, L | 1 |
| Cognetta, AB | 2 |
| Becquart, O | 1 |
| Guillot, B | 1 |
| Bourrain, JL | 1 |
| Duflos, C | 1 |
| Du-Thanh, A | 1 |
| van der Hoeven, NV | 1 |
| Zwinderman, AH | 1 |
| Kreutz, R | 1 |
| Algharably, EAH | 1 |
| Douros, A | 1 |
| Reeder, MJ | 1 |
| Wood, GS | 1 |
| Heinrichs, E | 1 |
| Walsh, SN | 1 |
| Kerchner, K | 1 |
| Sangüeza, OP | 1 |
| Jahan-Tigh, RR | 1 |
| Huen, AO | 1 |
| Lee, GL | 1 |
| Pozadzides, JV | 1 |
| Liu, P | 1 |
| Duvic, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Hydrochlorothiazide and the Risk of Skin Cancer[NCT04334824] | 2,953,748 participants (Actual) | Observational | 2019-05-27 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for hydrochlorothiazide and Cancer of Skin
| Article | Year |
|---|---|
Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis.
Topics: Aged; Carcinoma, Squamous Cell; Female; Humans; Hydrochlorothiazide; Lip; Lip Neoplasms; Male; Skin | 2022 |
Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population?
Topics: Adult; Carcinoma, Basal Cell; Humans; Hydrochlorothiazide; Incidence; Lip Neoplasms; Skin Neoplasms; | 2022 |
Associations of thiazide use with skin cancers: a systematic review and meta-analysis.
Topics: Bendroflumethiazide; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Indapamide; Melanoma; Sk | 2022 |
The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis.
Topics: Antihypertensive Agents; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Melanoma; Skin Neopla | 2023 |
Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Canada; | 2023 |
What is the relationship between photosensitizing drugs and skin cancer?
Topics: Dermatitis, Photoallergic; Dermatitis, Phototoxic; Humans; Hydrochlorothiazide; Photosensitivity Dis | 2023 |
Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinoma, Basal Cell; Humans; Hydrochlorothiazide | 2020 |
[Hydrochlorothiazide use and risk of skin cancers: A systematic review].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Melanoma; Risk Assessm | 2019 |
[Hydrochlorothiazide and skin cancer].
Topics: Blood Pressure; Carcinoma, Basal Cell; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Skin Ne | 2019 |
Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer.
Topics: Humans; Hydrochlorothiazide; Hypertension; Skin Neoplasms; Sodium Chloride Symporter Inhibitors | 2019 |
Drug-induced pseudo-Sezary syndrome: a case report and literature review.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Hydrochlorothiazide Use and Skin Cancer: A Mohs Surgeon's Concern.
Topics: Antihypertensive Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazid | 2016 |
58 other studies available for hydrochlorothiazide and Cancer of Skin
| Article | Year |
|---|---|
Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population.
Topics: Brazil; Carcinoma, Basal Cell; Case-Control Studies; Humans; Hydrochlorothiazide; Pilot Projects; Sk | 2022 |
The Risk of Cutaneous Squamous Cell Carcinoma Among Patients with Type 2 Diabetes Receiving Hydrochlorothiazide: A Cohort Study.
Topics: Aged; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Dr | 2021 |
Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide?
Topics: Antihypertensive Agents; Carcinoma, Basal Cell; Female; Humans; Hydrochlorothiazide; Male; Retrospec | 2022 |
The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region.
Topics: Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Basal Cell; Female; Humans; Hydrochlorothiazide | 2022 |
Hydrochlorothiazide use, sun exposure, and risk of keratinocyte cancer.
Topics: Adult; Aged; Humans; Hydrochlorothiazide; Keratinocytes; Retrospective Studies; Skin Neoplasms; Sunl | 2022 |
A reverse translational pharmacological approach to understand the underlying mechanisms of the reported association between hydrochlorothiazide and non-melanoma skin cancer.
Topics: Humans; Hydrochlorothiazide; Proteomics; Skin Neoplasms | 2022 |
Does systemic hydrochlorothiazide increase the risk of developing ultraviolet radiation-induced skin tumours in hairless mice?
Topics: Animals; Carcinoma, Squamous Cell; Hydrochlorothiazide; Mice; Mice, Hairless; Neoplasms, Radiation-I | 2023 |
Awareness and Counseling Among Dermatologists of the Association Between Hydrochlorothiazide and Nonmelanoma Skin Cancer: Barriers and Opportunities.
Topics: Antihypertensive Agents; Cross-Sectional Studies; Dermatologists; Humans; Hydrochlorothiazide; Hyper | 2023 |
Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study.
Topics: Aged; Cohort Studies; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Retrospect | 2023 |
Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study.
Topics: Adult; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cohort Studies; Humans; Hydrochlorothiazide; | 2023 |
MULTIPLE BCCS AND DYSPLASTIC NEVI AFTER ACE INHIBITORS (ENALAPRIL/PERINDOPRIL): THE ROLE OF NITROSAMINE CONTAMINATION/AVAILABILITY AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carcinogens; Dysp | 2023 |
The effect of hydrochlorothiazide on the recurrence of nonmelanoma skin cancer: a 7-year retrospective study comprising 300 patients.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Recurrence; Retr | 2023 |
Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ethnicity; Humans; Hydroch | 2023 |
Importance of accounting for timing of time-varying exposures in association studies: Hydrochlorothiazide and non-melanoma skin cancer.
Topics: Aged; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Incidence; Ontario; Skin N | 2023 |
Commentary on: "Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study.
Topics: Adult; Cohort Studies; Humans; Hydrochlorothiazide; Skin Neoplasms; White People | 2023 |
Phototoxic and carcinogenic effects of hydroclorothiazide: experimental study contrasting the pharmacoepidemiological evidence showing increased risk of skin cancer.
Topics: Humans; Hydrochlorothiazide; Skin Neoplasms | 2023 |
NITROSOGENESIS LESSONS FROM DERMATOLOGISTS-NITROSAMINES/ NDSRIS CONTAMINATION OF THE POLIMEDICATION IN POLIMORBID PATIENTS AS THE MOST POWERFUL SKIN CANCER INDUCTOR: DOUBLE HATCHET FLAP FOR SCC OF THE SCALP OCCURRING DURING TREATMENT WITH VALSARTAN/ HYDRO
Topics: Aged, 80 and over; Carcinogens; Carcinoma, Squamous Cell; Dermatologists; Humans; Hydrochlorothiazid | 2023 |
Thiazides and nonmelanoma skin cancer: Is it a class effect?
Topics: Case-Control Studies; Denmark; Humans; Hydrochlorothiazide; Skin Neoplasms; Thiazides | 2020 |
Reply to: "Thiazides and nonmelanoma skin cancer: Is it a class effect?"
Topics: Case-Control Studies; Denmark; Humans; Hydrochlorothiazide; Skin Neoplasms; Thiazides | 2020 |
Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Case-Control Studies; Female; Humans; Hydrochlorot | 2019 |
Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea.
Topics: Cohort Studies; Europe; Humans; Hydrochlorothiazide; Republic of Korea; Retrospective Studies; Skin | 2020 |
Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies.
Topics: Adult; Carcinoma, Basal Cell; Case-Control Studies; Humans; Hydrochlorothiazide; Incidence; Lip Neop | 2020 |
Comments on "Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study".
Topics: Asian People; Case-Control Studies; Humans; Hydrochlorothiazide; Hypertension; Skin Neoplasms | 2020 |
Comment on "Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea".
Topics: Humans; Hydrochlorothiazide; Hypertension; Republic of Korea; Retrospective Studies; Skin Neoplasms | 2020 |
Severe widespread actinic damage and squamous cell carcinoma: could hydrochlorothiazide be implicated? A report of two cases.
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Diuretics; Female; Humans; Hydrochlorothiazide; Middle | 2020 |
Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study.
Topics: Aged; Aged, 80 and over; Australia; Carcinoma, Squamous Cell; Case-Control Studies; Cohort Studies; | 2020 |
Squamous cell carcinoma of the dorsal hands and feet after repeated exposure to ultraviolet nail lamps.
Topics: Aged; Beauty Culture; Carcinoma, Squamous Cell; Female; Foot; Hand; Humans; Hydrochlorothiazide; Men | 2020 |
Response to comment on "Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea".
Topics: Humans; Hydrochlorothiazide; Hypertension; Republic of Korea; Retrospective Studies; Skin Neoplasms | 2020 |
Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, | 2021 |
RF - Thiazide Diuretics and Nonmelanoma Skin Cancer.
Topics: Diuretics; Humans; Hydrochlorothiazide; Skin Neoplasms; Sodium Chloride Symporter Inhibitors | 2021 |
Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer.
Topics: Cohort Studies; Humans; Hydrochlorothiazide; Melanoma; Risk Assessment; Skin Neoplasms; Sodium Chlor | 2021 |
Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.
Topics: Adult; Age Factors; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Databases, Factual; Diuretics; | 2020 |
Hydrochlorothiazide Associated with Risk of Skin Cancer.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Skin Neoplasms | 2020 |
Use of hydrochlorothiazide and risk of nonmelanoma skin cancer in Koreans: a retrospective cohort study using administrative healthcare data.
Topics: Age Factors; Aged; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Incidence; Kaplan-M | 2021 |
Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study.
Topics: Carcinoma, Basal Cell; Humans; Hydrochlorothiazide; Melanoma; Risk Factors; Skin Neoplasms; Spain | 2021 |
In Brief: Hydrochlorothiazide and skin cancer.
Topics: Antihypertensive Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Drug Labeling; Humans; Hyd | 2020 |
Cutaneous T-cell lymphoma after chronic exposure to hydrochlorothiazide: pharmacovigilance analysis from the RADAR (Research on Adverse Drug events And Reports) Program.
Topics: Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Hydrochlorothiazide; Ly | 2021 |
Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carcino | 2021 |
Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain.
Topics: Carcinoma, Basal Cell; Case-Control Studies; Humans; Hydrochlorothiazide; Skin Neoplasms; Spain | 2021 |
Increased cutaneous squamous cell carcinoma risk with hydrochlorothiazide use: is there a safe alternative?
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Case-Control Studies; Humans; Hydrochlorothiazide; | 2021 |
Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study.
Topics: Cell Line; DNA Damage; Humans; Hydrochlorothiazide; Keratinocytes; Melanoma; Oxidative Stress; Skin | 2021 |
Use of hydrochlorothiazide in Denmark following publication of skin cancer risk findings.
Topics: Cohort Studies; Denmark; Humans; Hydrochlorothiazide; Registries; Risk; Skin Neoplasms | 2021 |
Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; C | 2018 |
[Hydrochlorothiazide and skin cancer].
Topics: Carcinoma; Diuretics; Evidence-Based Medicine; Humans; Hydrochlorothiazide; Hypertension; Skin Neopl | 2018 |
Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Female; Humans; Hydrochlorothiazide; Male; Melan | 2018 |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study.
Topics: Age Distribution; Aged; Aged, 80 and over; Carcinoma, Merkel Cell; Case-Control Studies; Denmark; Do | 2019 |
Inflammation Due to Voriconazole-induced Photosensitivity Enhanced Skin Phototumorigenesis in Xpa-knockout Mice.
Topics: Animals; Antifungal Agents; Antihypertensive Agents; Cocarcinogenesis; Cytokines; Hydrochlorothiazid | 2018 |
[Hydrochlorothiazide appears to increase risk of melanoma].
Topics: Humans; Hydrochlorothiazide; Melanoma; Skin Neoplasms | 2018 |
Hydrochlorothiazide and the Risk of Malignant Melanoma.
Topics: Humans; Hydrochlorothiazide; Melanoma; Skin Neoplasms | 2018 |
Hydrochlorothiazide and the Risk of Malignant Melanoma-Reply.
Topics: Humans; Hydrochlorothiazide; Melanoma; Skin Neoplasms | 2018 |
The expanding saga of hydrochlorothiazide and skin cancer.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrochlorothiazide; | 2019 |
[Hydrochlorothiazide and nonmelanoma skin cancer].
Topics: Humans; Hydrochlorothiazide; Skin Neoplasms; Sodium Chloride Symporter Inhibitors | 2019 |
Reply to "Comment on 'Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark'".
Topics: Case-Control Studies; Denmark; Humans; Hydrochlorothiazide; Skin Neoplasms | 2021 |
Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark".
Topics: Case-Control Studies; Denmark; Humans; Hydrochlorothiazide; Skin Neoplasms | 2021 |
Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Risk Assessment; Risk Factors; S | 2019 |
Hydrochlorothiazide Use and Increased Squamous Cell Carcinoma Burden in a High-Risk Mohs Population: A Cross-Sectional Study.
Topics: Aged; Carcinoma, Squamous Cell; Cross-Sectional Studies; Diuretics; Female; Florida; Humans; Hydroch | 2020 |
Challenge. What is your diagnosis? Answer. Primary nodal diffuse large B-cell lymphoma with secondary cutaneous involvement.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; C | 2009 |
Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series.
Topics: Aged; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Mycosis Fungo | 2013 |